Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel

Platelet Aggregation and Adenosine Levels Among Patients With Stable Chronic Coronary Artery Disease Taking Ticagrelor or Prasugrel

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05247385

Enrollment

Registered

2022-02-18

Start date

2017-03-20

Completion date

2021-12-20

Last updated

2022-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

Prospective, single-center, double blind, double dummy, randomized trial. Platelet function tests and adenosine levels were assessed at baseline and 15 days after taking Ticagrelor with Prasugrel placebo or Prasugrel with Ticagrelor placebo in stable patients with coronary artery disease

Detailed description

This was a prospective, double blinded, randomized trial that compared platelet inhibition and adenosine levels with ticagrelor (180mg loading dose, followed by 90 mg BID) versus prasugrel (60mg loading dose, followed by 10 mg QD) . Patients were eligible if they were between 18 and 75 years old, were on aspirin without P2Y12 inhibitor at baseline and \> 1 year after documented ACS. Platelet aggregation was compared with the Multiplate ADP® assay, performed at baseline and after 15 days on study medication. Adenosine plasma levels were measured with high performance liquid chromatography at the same time points

Interventions

DRUGPrasugrel

Compared platelet inhibition and adenosine levels at baseline and after 15 days

DRUGTicagrelor

Compared platelet inhibition and adenosine levels at baseline and after 15 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* between 18 and 75 years old * were on aspirin * without P2Y12 inhibitor at baseline * \> 1 year after documented acute coronary syndrome

Exclusion criteria

* use of oral anticoagulation or P2Y12 at baseline * Weight \< 60kg * History of tia or stroke * Any coagulation disorders * Refuse to sign the written consent

Design outcomes

Primary

Measure	Time frame	Description
To compare platelet inhibition between the two groups (ticagrelor and prasugrel)	15 days	Platelet aggregation was compared with the Multiplate ADP® assay at baseline and after 15 days on study medication
To compare adenosine levels between the two groups (ticagrelor and prasugrel)	15 days	Adenosine plasma levels were measured at baseline and after 15 days with high performance liquid chromatography at the same time points

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026